This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Health indices saw a better trading day Tuesday as stocks rose on data and a bit of business strategizing.

Barrier Therapeutics (BTRX) rose 42 cents, or 12.4%, to $3.78 after announcing positive results from a safety, dose-escalation study of its oral antifungal drug, pramiconazole. The company used a 6-gram dose, 30 times higher than the single weekly dose that's currently being used in a phase IIa study in toenail fungus. Barrier said that no clinically relevant changes were seen in 32 volunteers dosed with up to 6 grams of the drug over a five-day period compared to placebo.

Osiris Therapeutics (OSIR - Get Report) gave positive interim, one-year results of a 55-patient, phase I/II trial evaluating Chondrogen, a preparation of adult stem cells formulated to be injected into the knee. The company said the one-year data showed improvement in joint condition and that patients with osteoarthritis who were treated with Chrondrogen saw clinically and statistically significant improvement in pain compared with those treated with hyaluronic acid, the control. Shares rose $1.53, or 15%, to $11.77.

After announcing Monday that it terminated its MAXY alpha (a treatment for hepatitis B and hepatitis C) development with partner Roche, Maxygen (MAXY) said Tuesday that it will consolidate all of its operations in its U.S. headquarters in Redwood City, Calif., adding 25 employees. The company will cease operations of Maxygen ApS, its subsidiary in Denmark, where it employs a primarily scientific staff in preclinical research. The company said it expects to garner $10 million in annual cost savings from the move starting in 2008. Shares edged up 17 cents, or 2.4%, to $7.29.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MAXY $0.00 0.00%
MRK $54.81 0.00%
OSIR $5.01 0.00%
UNH $132.03 0.00%
THC $31.46 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs